Jacqueline Greer
Overview
Explore the profile of Jacqueline Greer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evans M, Sung A, Gojo I, Tidwell M, Greer J, Levis M, et al.
Leuk Lymphoma
. 2011 Sep;
53(4):660-4.
PMID: 21942284
CD4 count ≤200×10(6) cells/L has been identified as a predictor of short survival in HIV-associated acute myeloid leukemia (HIV-AML), but karyotype, which is the best predictor of survival in AML,...
2.
Kaufmann S, Karp J, Litzow M, Mesa R, Hogan W, Steensma D, et al.
Haematologica
. 2011 Jul;
96(11):1619-26.
PMID: 21791475
Background: In preclinical studies the heat shock protein 90 (Hsp90) inhibitor tanespimycin induced down-regulation of checkpoint kinase 1 (Chk1) and other client proteins as well as increased sensitivity of acute...
3.
Karp J, Smith B, Gojo I, Lancet J, Greer J, Klein M, et al.
Clin Cancer Res
. 2008 May;
14(10):3077-82.
PMID: 18483374
Purpose: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features. Such patients might benefit from additional therapy in complete remission (CR). Tipifarnib...
4.
Karp J, Smith B, Levis M, Gore S, Greer J, Hattenburg C, et al.
Clin Cancer Res
. 2007 Aug;
13(15 Pt 1):4467-73.
PMID: 17671131
Purpose: Flavopiridol is a cyclin-dependent kinase inhibitor that is cytotoxic to leukemic blasts. In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for...
5.
Karp J, Giles F, Gojo I, Morris L, Greer J, Johnson B, et al.
Leuk Res
. 2007 Jul;
32(1):71-7.
PMID: 17640728
Triapine is a potent ribonucleotide reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially dATP. We designed a Phase I trial of Triapine followed by the adenosine analog fludarabine in...
6.
Karp J, Ricklis R, Balakrishnan K, Briel J, Greer J, Gore S, et al.
Blood
. 2007 Jun;
110(6):1762-9.
PMID: 17562873
Clofarabine has shown impressive response rates in patients with acute leukemias. In vitro investigations with clofarabine in combination with cyclophosphamide in primary cells have demonstrated synergistic cytotoxicity and inhibition of...
7.
Gojo I, Tidwell M, Greer J, Takebe N, Seiter K, Pochron M, et al.
Leuk Res
. 2007 Feb;
31(9):1165-73.
PMID: 17324462
Triapine, a potent inhibitor of ribonucleotide reductase, has demonstrated anti-leukemia activity in pre-clinical models. We conducted a Phase I study of Triapine administered as a 2 h infusion for 5...
8.
Gojo I, Jiemjit A, Trepel J, Sparreboom A, Figg W, Rollins S, et al.
Blood
. 2006 Dec;
109(7):2781-90.
PMID: 17179232
MS-275 is a benzamide derivative with potent histone deacetylase (HDAC) inhibitory and antitumor activity in preclinical models. We conducted a phase 1 trial of orally administered MS-275 in 38 adults...
9.
Lancet J, Gojo I, Gotlib J, Feldman E, Greer J, Liesveld J, et al.
Blood
. 2006 Nov;
109(4):1387-94.
PMID: 17082323
Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib...
10.
Karp J, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella T, et al.
Clin Cancer Res
. 2005 Dec;
11(23):8403-12.
PMID: 16322302
Purpose: The serine/threonine kinase inhibitor flavopiridol targets multiple cyclin-dependent kinases, induces checkpoint arrest, and interrupts transcriptional elongation. We designed a phase I clinical trial using a timed sequential therapy approach...